{Reference Type}: Journal Article
{Title}: Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study.
{Author}: Mazzitelli M;Antoni MD;Castelli F;Ripamonti D;Zuglian G;Lapadula G;Fabbiani M;Ferraresi A;Putaggio C;Cattelan AM;Quiros-Roldan E;
{Journal}: Medicine (Baltimore)
{Volume}: 101
{Issue}: 30
{Year}: Jul 2022 29
{Factor}: 1.817
{DOI}: 10.1097/MD.0000000000029855
{Abstract}: Use of doravirine (DOR), a new nonnucleoside reverse-transcriptase inhibitors recently approved for HIV treatment, is still unclear in clinical practice and real-life data are scarce. We retrospectively investigated the rationale for switching people with HIV to DOR-containing/-based regimens in a real-life cohort. Among 132 patients (68.9% males, median age 56 years), the main reasons to start DOR were prevention of toxicities (39.4%) and dyslipidemia (18.2%). DOR was combined with integrase inhibitors in 40.9% cases, and in 25.7% of patients, DOR was prescribed without availability of a genotypic resistance test. Twenty-four weeks after the switch to DOR-containing/-based regimens, no significant changes in CD4+ T-cell count, CD4/CD8 ratio, detectable HIV-RNA, serum creatinine levels, and body weight were detected. By contrast, a significant reduction in lipids (both cholesterol and triglycerides) was observed in 52 patients for whom a follow-up assessment was available (P = .008 and .01, respectively). Our data confirmed that switching to DOR-containing/-based regimens may have a favorable impact on lipid profile and a neutral impact on weight gain. However, more data are needed to support its use in patients who do not have a genotypic test available or have an extensive nonnucleoside reverse-transcriptase inhibitors-associated resistance, as well as its use in a dual regimen, especially in combination with second-generation integrase inhibitors.